
The current investigation was on synthesis, characterization and molecular docking studies of novel 4-anilinoquinazoline derivatives for their anti-tumor effects.The synthesized novel 4-anilinoquinazoline derivatives were characterized using 1H and 13C Nuclear magnetic resonance (NMR), Infrared (IR) and mass spectroscopic analysis. Compounds PR (1-6) were screened for cytotoxicity assays against various cell lines such as HCT116, K562, SKBR3 and EAC cell lines using MTT assay, trypan blue dye exclusion and LDH release assay. The molecular docking studies were drawn using Maestro 2D sketcher and energy minimize was computed by OPLS 2005. Proteins were prepared by retrieving into Maestro platform Schrödinger, Inc.PR-6 enhanced cytotoxic activity in the range of 10.09±0.92 to 11.24±0.81 µM on all four cell lines, which is comparable to that of standard drugs cisplatin (6.4±1.45 to 8.48±0.63 µM) and doxorubicin (7.89±091 to 8.48±1.02 µM). Furthermore, molecular docking studies of synthesized compounds PR (1-6) as vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) inhibitors were performed on crystal structure of VEGFR-2 and EGFR and amongst them PR-6 has shown maximum docking score (-11.13) against VEGFR-2. This finding strongly suggested that PR-6 is effective cytotoxic agent against all the four cancer cell lines in-vitro and also significant angiogenic inhibitor as ascertained by its potential interaction with VEGFR-2 and EGFR.